A Study of the Natural History of Leukocyte Chemotactic Factor 2 Amyloidosis (ALECT2) Disease

Alnylam Pharmaceuticals

Status: Terminated

Conditions: Leukocyte Chemotactic Factor 2 Amyloidosis; Amyloidosis

Study type: Observational

Funder types: Industry

Identifiers

NCT03774784

ALN-LECT2-NT-001

Details and patient eligibility

About

The purpose of this study is to characterize the natural history of leukocyte chemotactic factor 2 amyloidotic (ALECT2) disease. In this observational study participants with ALECT2 disease will be enrolled. Participants, who have already reached end-stage renal disease (ESRD), will provide retrospective chart review data and biological specimens at baseline only. Other participants, in addition to retrospective chart review, will be followed prospectively.

Full description

Refer to www.studyALECT2.com

Enrollment: 26 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Males and females, age 18 years or older;
• Renal biopsy-proven diagnosis of ALECT2;
• For patients with kidney disease that could be due to ALECT2, a renal biopsy may be obtained to confirm ALECT2 diagnosis.

Exclusion criteria

• There are no exclusion criteria for this observational study.

Trial design

26 participants in 1 patient group

ALECT2 Disease